What smart money is saying about BioNTech
BNTX
No fund has written a full thesis on BioNTech in our archive, but 2 fund letters report a position in it, most recently Baillie Gifford International Alpha in September 2026.
Get an email when a fund buys, sells or pitches it
2
Reported positions
0
Bought
2
Sold
2
Letters
Position history
Between Q2 2026 and Q3 2026, 2 fund letters reported a position in BioNTech, with 2 sells (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 1 | 0 |
| Q2 2026 | 1 | 0 | 1 | 0 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 2 positions · 2 moves
- September 2026
“With the repositioning largely complete after a busy summer, we are happy with the shape of the portfolio, so trading activity slowed this quarter. The sales we did make came from our process, doing what it is designed to do. Every holding needs a sponsor and a seconder within the team to remain in the portfolio, and when either loses conviction, we sell. That led us to exit a small number of companies whose operational progress or prospective returns had fallen short, among them German biotechnology company BioNTech and Japanese mergers and acquisitions adviser Nihon M&A.”
BioNTech - June 2026
“We also sold our holding in the German biotechnology company BioNTech, where the abrupt announcement of the founders' departure, including the CEO, raised governance concerns we were unable to resolve.”
BioNTech
Read the letters behind these BioNTech positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves, and to Warren AI, which reads all of them for you.
View plans→Share this ledger